How to Improve Cytotoxic Therapy in Advanced Breast Cancer
- 1 January 1990
- journal article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 29 (3), 349-355
- https://doi.org/10.3109/02841869009090013
Abstract
The optimal cytotoxic treatment of patients with advanced breast cancer is so far not defined. Median survival after first metastatic manifestation is approximately 18 months. No direct evidence for a survival improvement after the introduction of cytotoxic therapy has been published. Major efforts have been made to improve treatment efficacy through manipulations of doses, schedules and combinations of known cytotoxic drugs. Three months is probably too short a treatment period. Alternating non-cross resistant regimens offer no advantage over sequential therapy. A dose-response relationship clearly exists in breast cancer, but the higher response rates have not been transformed into a survival benefit. Treatment of advanced breast cancer is palliative, and if, furthermore, we have actually reached a plateau where no further improvement in survival is possible, we will have to evaluate every new treatment modality carefully according to quantity as well as quality of life.Keywords
This publication has 15 references indexed in Scilit:
- Distant Recurrence in Breast Cancer: Survival expectations and first choice of chemotherapy regimenActa Oncologica, 1988
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour drugs in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1987
- Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?Cancer, 1986
- Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Comparison of consecutive series of patients in 1950s, 1960s, and 1970sCancer, 1985
- Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group studyCancer, 1984
- Prospective evaluation of rotating chemotherapy in advanced breast cancerAmerican Journal of Clinical Oncology, 1983
- Randomized study of high-dose versus low-dose methotrexate in the treatment of extensive small cell lung cancerAmerican Journal Of Medicine, 1982
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCERThe Lancet, 1980